In this paper, we show how some proposals within the Minimalist Program are compatible with a model of codeswitching that recognizes an asymmetry between the participating languages, the Matrix Language Frame model. Through our discussion of an analysis of NPs in a Spanish–English corpus, we illustrate this compatibility and show how recent minimalist proposals can explain the distribution of nouns and determiners in this data set if they adopt the notion of Matrix Language as the bilingual instantiation of structural uniformity in a CP. We outline the central premises of the Matrix Language Frame model, and introduce the Uniform Structure Principle which requires that the structure of constituents be uniform at an abstract level. We then review previous applications of the Minimalist Program to codeswitching.Much recent research in minimalism has focused on issues related to feature checking. Earlier approaches to feature checking required matching of features in grammatical structures, although more recent proposals consider distinctions in the values of features and in types of matching. Because phi-features for grammatical gender in Spanish and English differ, an analysis of NPs in this corpus of naturally occurring Spanish–English conversations provides a test for minimalist applications to codeswitching. We present our general findings of the distribution of types of NP constituents and then consider explanations of these distributions in light of minimalist proposals. It is possible to explain these distributions in a recasting of the Matrix Language Frame model in minimalist terms, if the construct of the Matrix Language is maintained. The requirement that one language, the Matrix Language, provide an abstract grammatical frame in bilingual constituents corresponds to the type of uniformity that Chomsky (2001) suggests is necessary for the explanatory study of language and variation in language.
Summary
Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus CE in extensive-stage disease small cell lung cancer (ED-SCLC). Methods This exploratory analysis of a phase II study evaluated CXCR4 expression in baseline tumor tissue and peripheral blood CTCs and in post-treatment CTCs. Optimum cutoff values were determined for CTC counts and CXCR4 expression in tumors and CTCs as predictors of survival outcome. Kaplan-Meier estimates and hazard ratios were used to determine biomarker prognostic and predictive values. Results There was weak positive correlation at baseline between CXCR4 expression in tumor tissue and CTCs. Optimum cutoff values were H-score ≥ 210 for CXCR4+ tumor, ≥7% CTCs with CXCR4 expression (CXCR4+ CTCs), and ≥6 CTCs/7.5 mL blood. Baseline H-score for CXCR4+ tumor was not prognostic of progression-free survival (PFS) or overall survival (OS). Baseline CXCR4+ CTCs ≥7% was prognostic of shorter PFS. CTCs ≥6 at baseline and cycle 2, day 1 were prognostic of shorter PFS and OS. None of the biomarkers at their respective optimum cutoffs was predictive of treatment response of LY2510924 plus CE versus CE. Conclusions In patients with ED-SCLC, baseline CXCR4 expression in tumor tissue was not prognostic of survival or predictive of LY2510924 treatment response. Baseline CXCR4+ CTCs ≥7% was prognostic of shorter PFS. CTC count ≥6 at baseline and after 1 cycle of treatment were prognostic of shorter PFS and OS.Electronic supplementary materialThe online version of this article (doi:10.1007/s10637-017-0446-z) contains supplementary material, which is available to authorized users.
SummaryWe have developed an automated assay to enumerate and characterize circulating multiple myeloma cells (CMMC) from peripheral blood of patients with plasma cell disorders. CMMC show expression of genes characteristic of myeloma and fluorescence in situ hybridisation results on CMMC correlated well with bone marrow results. We enumerated CMMC from over 1000 patient samples including separate cohorts of newly diagnosed multiple myeloma and high/intermediate risk smouldering multiple myeloma (SMM) with clinical follow-up data. In newly diagnosed myeloma patient samples, CMMC counts correlated with other clinical measures of disease burden, including the percentage of bone marrow plasma cells, serum M protein, and International Staging System stage. CMMC counts decreased significantly from baseline when a remission was achieved due to treatment (P < 0Á001). Patients with CMMC counts ≥100 at remission showed reduced survival relative to patients with CMMC counts <100. Patients with undetectable CMMC in remission showed further overall survival benefits. In the SMM cohort, there was a trend toward higher CMMC in patients with higher-risk myeloma precursor states. Significantly higher CMMC counts were observed between intermediate/high risk SMM patients that progressed versus those without progression (P = 0Á031). CMMC allow a non-invasive means of monitoring tumour biology and may have use as a prognostic test for patients with plasma cell disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.